An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
NCT ID: NCT05462535
Last Updated: 2022-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4785 participants
OBSERVATIONAL
2018-02-26
2021-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
During the routine medical visit, Amosartan Plus tablets were administered to patients in need of blood pressure control according to the investigator's judgment.
In this study, effectiveness and safety information of treatment of Amosartan Plus tablets was followed for 6 months (up to 12 months), and observation of the target patients was terminated after collecting relevant data.
As this study was a non-interventional observational study, all patients received prescriptions according to the routine treatment procedure, and there were no visits or procedures required according to the observational study protocol.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet
NCT05450575
Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure
NCT03255551
The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
NCT01828359
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers
NCT02166398
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
NCT05476354
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data was collected from patients receiving routine treatment at hospitals in South Korea. Each patient visited the institution according to the protocol that designed the follow-up visits for six months to examine the effectiveness and safety of Amosartan Plus tablet.
This study approved by the institutions' IRBs and was conducted in compliance with clinical research ethics regulations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm, Single group(No interventional)
Observational
Amosartan Plus Tab.
Amosartan Plus Tab., Once daily administered per the locally approved product information
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amosartan Plus Tab.
Amosartan Plus Tab., Once daily administered per the locally approved product information
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those who have already decided to administer Amosartan Plus tablet under the medical judgment of the researcher
* Those who voluntarily decided to participate in this study and consented in writing to the consent form
Exclusion Criteria
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanmi Pharmaceutical Company Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanmi Pharmaceutical Company Limited
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM-AMOP-OS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.